Life Science News

Aptose Biosciences to Present at Biotech Showcase 2023 Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10 th 2023, at 10:00 a.m. PST in San Francisco, CA.

Conference Presentation Details:

Date: Tuesday, January 10, 2023
Time: 10:00 a.m. PST
Location: Track Yosemite - C (Ballroom Level)
Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA 94102
Webcast: LINK

The audio webcast will be archived shortly after the live event and will be available through the Aptose website, www.aptose.com.

The Company also will be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco on January 9-11, 2023. To schedule a meeting with Aptose, investors can request a meeting on the online system here .

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (formerly HM43239), an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com .

For further information, please contact:

Aptose Biosciences Inc. LifeSci Advisors, LLC
Susan Pietropaolo Dan Ferry, Managing Director
Investor Relations 617-535-7746
201-923-2049 Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com




Primary Logo

News Provided by GlobeNewswire via QuoteMedia

APS:CA,APTO
The Conversation (0)

Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

- Commitments demonstrate leadership in advancing health equity and workforce representation to better serve patients and communities

- $10 million in 2023 grant funding to 17 U.S. organizations focused on addressing social determinants of health

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Boosh Announces the Closing of its Private Placement Offering and Opens Listing Issuer Exemption Offering

Boosh Announces the Closing of its Private Placement Offering and Opens Listing Issuer Exemption Offering

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement financing. In total, the Company has raised $362,000.00 CAD via the sale of 7,240,000 Units. Each Unit is comprised of one Common Share of the Company and one Purchase Warrant, with each Warrant exercisable into one Common Share of the Company at a price of $0.07 CAD at any time on or before the date which is 12 months from the closing of the offering. In connection with the offering, the Company paid $1,750.00 CAD in finders fees. Proceeds from the Offering will be used for general working capital purposes and to further advance the Company's business.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

- More than 20 abstracts, including one late-breaking presentation, underscore AbbVie's dedication to advancing care for dermatologic conditions

ABBVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American Academy of Dermatology (AAD) Annual Meeting, March 17-21 in New Orleans, Louisiana .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

Aptose Biosciences Inc. ("Aptose" or the "Company") (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, is aware of reports related to Silicon Valley Bank ("SVB") and questions raised by interested parties.

Aptose has not entered into a line of credit with SVB, and therefore has no exposure related to any credit facility.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2023 Oppenheimer Healthcare Conference at 2:00 p.m. ET on Monday, March 13, 2023 . Susan Sweeney senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, March 23, 2023, after the close of the market, and provide a corporate update.

Conference Call & Webcast:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×